CRISPR Therapeutics (CRSP) pipeline and stated timing
Name in SEC filings: CRISPR Therapeutics
No current calendar date is shown here. Retained program statements and source dates appear below.
Programs and stated timing
○ Quote matched to filing (not yet reviewed by founder) · ✓ Checked by founder.
No source-verified calendar row is retained.
How this date was described over time
Company periods and sentences are quoted as written. A matching disclosure uses the SEC filing date for the same program and event type. As of .
No additional verified wording history is retained.
“Not compared” means ORION has not matched this wording against a complete set of SEC filings for its period. It says nothing either way about whether a matching filing exists. Wording without exact dates is not given calendar dates.
Retained company announcements
Historical summaries and source dates are retained separately from the SEC timing quotes above. Earlier publications were collected retrospectively.
Retained summary: CRISPR and Vertex reported a December 8, 2023 FDA target date for the sickle cell disease application. The separate thalassemia application had a different target and is not combined into this milestone.
Retained summary: Vertex and CRISPR announced FDA approval of CASGEVY for sickle cell disease in patients aged 12 years and older with recurrent vaso-occlusive crises.
These are selected linked records and dated source metadata, not a live registry recheck or the company’s full pipeline. Company announcements and the selected registry study are separate evidence sets. No stage or event timing is borrowed between them.
The timing wording in the earliest company statement located within the sources checked, quoted as written (for example “2H 2026”). An earlier statement may exist outside those sources.
Disclosure date
The date of the filing or company release that disclosed the readout. “None found” means no such disclosure was located in the sources checked. SEC filings were searched through the “SEC filings searched through” date shown.
1H, 2H, 1Q–4Q
First or second half, or first to fourth quarter, of the year named, as the company wrote it. Equivalent notations are compared together; the original wording stays visible.
SEC original
The filing as published on the SEC EDGAR system. “Company original” is the release on the company's own investor site.
Status
One of seven labels set by founder review of the original filings. Definitions: Methodology.